Novartis AG

Novartis agreed to acquire New York-based biotech Tourmaline Bio for $1.4 billion, paying $48 per share in cash, representing a 60% premium to the company's Monday closing price.

Novartis announced the acquisition of Tourmaline Bio for approximately $1.4 billion, offering $48 per share in cash to complement its cardiovascular disease portfolio.

NRG Therapeutics secured £50 million ($67 million) in Series B funding to advance its lead compound NRG5051 into clinical trials for Parkinson's disease and ALS.

Jiangsu Hengrui Pharmaceuticals has licensed its selective myosin blocker HRS-1893 to Delaware-based startup Braveheart Bio for $65 million upfront plus potential milestone payments exceeding $1 billion.

Octave Bioscience closed a $35.6 million Series C equity financing round and secured a $15.5 million non-dilutive term loan from Silicon Valley Bank to accelerate commercialization of its precision neurology platform.

Novartis has signed an up to $5.2 billion licensing and options deal with China-based Argo Biopharmaceutical for experimental cardiovascular drugs using RNA interference technology.

Argo Biopharma and Novartis announced a multi-asset licensing agreement worth up to $5.2 billion focused on siRNA therapeutics for cardiovascular diseases.

Biotech leaders John Maraganore and Clive Meanwell have launched Corsera Health with the ambitious goal of creating a world without cardiovascular disease.

ACROBiosystems and DAAN Biotherapeutics signed a strategic MOU to establish a multi-faceted collaboration framework for developing precision immunotherapies targeting drug-resistant cancers.

Eli Lilly's Verzenio plus endocrine therapy demonstrated statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone in patients with HR+, HER2-, node-positive, high-risk early breast cancer.